Agree all the way polkadot, for Leo heading into this conference it is all about leverage. Leverage from the science in being able to project confidence about where Kevetrin stands, and leverage in being able to say from a finance standpoint that the company can go it alone if need be. I think this is all being played out masterfully right before our eyes. But the ultimate proof will be if all of this momentum translates into a big pharma putting pen to paper and putting money behind brilacidin.